

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

L-428

RRID:CVCL_1361

Type: Cell Line

Proper Citation

RRID:CVCL_1361

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1361

Proper Citation: RRID:CVCL_1361

Description: Cell line L-428 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Hodgkin lymphoma

Defining Citation: [PMID:2690233](#), [PMID:2898211](#), [PMID:3713248](#), [PMID:6303739](#), [PMID:6305805](#), [PMID:7216541](#), [PMID:7276066](#), [PMID:8547074](#), [PMID:8558920](#), [PMID:9685479](#), [PMID:9787181](#), [PMID:11021758](#), [PMID:12133989](#), [PMID:17065008](#), [PMID:19380639](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29533902](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: L-428

Synonyms: L 428, L428

Cross References: BTO:BTO_0000406, CLO:CLO_0007189, EFO:EFO_0002225, CLDB:cl3081, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-

MTAB-7722, BioSample:SAMN03473371, BioSample:SAMN10988569, cancercellines:CVCL_1361, Cell_Model_Passport:SIDM00327, ChEMBL-Cells:ChEMBL3308873, ChEMBL-Targets:ChEMBL2366233, CLS:300200, Cosmic:850218, Cosmic:907322, Cosmic:988703, Cosmic:1013907, Cosmic:1086358, Cosmic:1278830, Cosmic:1289698, Cosmic:1432036, Cosmic:1714161, Cosmic:2276326, Cosmic:2361389, Cosmic:2464304, Cosmic:2804876, Cosmic-CLP:907322, DepMap:ACH-000754, DSMZ:ACC-197, DSMZCellDive:ACC-197, EGA:EGAS00001000978, GDSC:907322, GEO:GSM499721, GEO:GSM499729, GEO:GSM552447, GEO:GSM637988, GEO:GSM887260, GEO:GSM888335, GEO:GSM1670029, IARC_TP53:21455, IARC_TP53:23612, IGRhCellID:L428, LiGeA:CCLE_448, LINCS_LDP:LCL-2011, Lonza:924, PharmacDB:L428_815_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_1361, PubChem_Cell_line:CVCL_1361, Wikidata:Q54900867

ID: CVCL_1361

Record Creation Time: 20220427T220712+0000

Record Last Update: 20260913T004713+0000

Ratings and Alerts

No rating or validation information has been found for L-428.

No alerts have been found for L-428.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Matos A, et al. (2026) Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis. International journal of cancer, 159(3), 782.

Shen Y, et al. (2025) Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e09103.

Caillot M, et al. (2023) Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma. Molecular oncology, 17(12), 2546.

Briest F, et al. (2023) Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Leukemia, 37(11), 2237.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Bein J, et al. (2022) T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma. *Journal of cellular and molecular medicine*, 26(12), 3495.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Haumann S, et al. (2020) Mitochondrial DNA mutations induce mitochondrial biogenesis and increase the tumorigenic potential of Hodgkin and Reed-Sternberg cells. *Carcinogenesis*, 41(12), 1735.

Bankov K, et al. (2019) Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury. *Cancers*, 11(11).